Curriculum Vitae

Prof. Dr. med. Nadezda Basara

eMail: brabanad@gmail.com

DOB: 16. November 1957

Place: Belgrad, Serbien

Nationality: German, Serbian, Montenegro

Family: married since 1982

Children: 2 (Sun born 1983 and Daughter born1988)

Name: **Professor Dr. med. habil. Nadezda Basara**
Nationality: Serbian/German/Montenegro

2011- 2023 Director of department Internal Medicine and Head of Oncological Center Nord at the University of UKSH, *Malteser St. Franziskus Hospital Flensburg, Germany*
Oncological Center Nord has been awarded DGHO accreditation.
BMT center has been registered an EBMT and DRST and has been awarded an international JACIE accreditation

2016 Visiting Professor Medical Faculty, University of Belgrade

2011 Visiting Professor Medical Faculty University of Nis

2005-2010 Head of Hematology/Oncology- Department and BMT- Unit and Qualified Person of Stem Cell Processing at the *University of Leipzig*, *Germany*.
More than 200 transplants per year, most of them allogeneic.

2007 Professor title at the *University of Leipzig, Germany.*

2003 Docent title at the *University of Mainz, Germany*

1997-2004 Head of Hematology/Oncology- Department and Qualified Person of Stem Cell Processing, University of Mainz, *Hospital Idar- Oberstein, Germany.*
More than 100 allogeneic transplants per year, most of them being unrelated.

1993-1997 Head of Department of Hematological Diagnostic, *University of Belgrade, Serbia*

1993 Doctor of science, University of Belgrade

1990-1991 *Hopital Hotel-Dieu* and *Hopital Lariboisier, Paris, France*

1988-1997 *University of Belgrade,Serbia*

1986-1987 *McGill University, Montreal, Canada*, Clinical Fellow at the BMT Unit

1985 Master of science, University of Belgrade

1984-1988 Research Fellow in Hematology and Experimental Medicine, Belgrade

1982-1984 Clinical Fellow at the University Hospital Belgrade

1982 M.D., *University of Belgrade, Serbia*

Studies as Principal Investigator

from 2011 to July 2023

A phase 3 randomized double-blind, placebo controlled study evaluating the safety and efficacy of Magrolimab versus placebo in combination with Venetoclax and Azacitidine in newly diagnosed previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, Principal Investigator

DSMM XVII Studie: Elotuzumab (E) im Kombination mit Karfilzomib, Lenalidomid und Dexamethason (E-KrD) gegen KrD vor und nach autologe Stammzelltransplantation bei neu diagnostiziertem Multiplem Myelom. Eine Phase III Studie der Deutschen Studiengruppe Multiples Myelom, Principal investigator

EudraCT: 2014-005130-55: HD21 Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma, comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD for advanced stages, Principal Investigator

GHSG AFM13 Protokol für fortgeschrittenen, refraktäre Stadien d. M.Hodgkin, Prinicipal Investigator

GO 29537: A Phase III multicentre randomizes open label study evaluating the efficacy and safety of atezolizumab in combination with carboplatin + nab-paclitaxel for chemotherapy-naïve patients with stage IV non squamous non small cell lung cancer. Prinicipal investigator

MC-FludT.14/L Eudra-CT: 2008-002356-18: Phase III Studie zum Vergleich von einer mit Busulfan basierten (reduzierten Intensität) Konditionierung vor allogener Stammzelltransplantation bei Patienten mit AML oder MDS bei denen eine Standardtherapie angewendet werden kann. Principal Investigator

HOVON 150AML/AMLSG 29-18
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an *IDH1* or *IDH2* mutation, respectively, eligible for intensive chemotherapy. Prinicipal Investigator

AMLSG 30-18 CPX351 Vyxeos
Randomized Phase III Study of Standard Intensive Chemotherapy *versus* Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics. Prinicipal Investigator

AMLSG Viva, Phase II, randomisiert
Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-*trans* retinoic acid and pioglitazone versus standard dose azacitidine in patients □60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy. Principal Investigator

AMLSG 11-08: Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance

Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML). Principal Investigator

AMLSG 12-09: Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. Principal Investigator

AMLSG 15-10: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-*Trans* Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and *NPM1* Mutation. Principal Investigator

Eudra-CT: 2011-003168-63: AMLSG16-10/CPKC412ADE02T: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a *FLT3* internal tandem duplication. Principal Investigator

Eudra-CT: 2009-011889-28: AML 09-09: Phase III Studie zu Chemotherapien in Kombination mit All-Trans-Retinsäure mit oder ohne Gemtuzumab Ozogamicin bei Patienten mit AML und Mutation im Nucleophosmin 1Gen. Principal Investigator

Eudra-CT: 2009-016616-21: DSMM XIV: Lenalidomide, Adriamycin, Dexamethasone (RAD) *versus* Lenalidomide, Bortezomib, Dexamethasone (VRD) For Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom. Subinvestigator

CC-4047-MM-015, Eudra CT: 2013-005542-11: A Non-Interventional post authorization registry of patients treated with Pomalidomide for relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both Lenalidomid and Bortezomib, and have demonstrated disease progression on the last therapy. Principal Investigator

HD18 für fortgeschrittene Stadien: Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms:Therapiestratifizierung mittels FDG-PET. Investigator

AIO-STO-0309 (POWER): Eine offene, randomisierte Phase III-Studie zu Cisplatin und 5Fluorouracil mit oder ohne Panitumumab bei Patienten mit nicht-resektablem, fortgeschrittenen oder metastasierten Plattenepitelkarzinom des Ösophagus. Investigator

AIO Trial KRK 0207

Optimal Maintenance Therapy with Bevacizumab after Induction in Metastatic CRC Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimidine and bevacizumab vs. bevacizumab alone vs. no maintenance treatment and reinduction in case of progression for first-line treatment of patients with metastatic colorectal cancer. Investigator

2010-2011

A randomized, multi-centre, parallel-group, open-label, Oncaspar controlled dose ranging trial of three doses of pegylated recombinant asparaginase in adult patients with newly diagnosed acute lymphoblastic leukemia. Principal Investigator

2010- 2011

A randomized, Multicentre, Phase II Trial to compare the Event-Free Survival of Clofarabine /ara-C (ClaraC) or of FLAMSA Treatment in patients with High-Risk Leikemia or Advanced MDS scheduled for Allogeneic Stem Cell Transplantation. Principal Investigator

2009- 2011

HCT vs CT elderly AML. Investigator

2008 – 2011

Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Ganzkörperbestrahlung, Principal Investigator

2007 - 2009

A Double-Blind, Randomised, Placebo-controlled Study of Two Different Schedule of Palifermin (Pre-and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) – 20050219, Iinvestigator

2006 - 2009

A Randomized double blinded placebo-controlled trial comparing Cyclosporine plus steroids with or without Myfortic as primary treatment for extensive chronic graft-versus host disease, An EBMT sponsored trial in chronic GvHD, Principal Investigator

2005 - 2009

A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with UVADEX* for the Treatment of Patients with Newly Diagnosed Acute Graft-versus-Host Disease, Investigator

2003 – 2011 Prognostic factors in MUD-ALL, EBMT Protocol, Principal Investigator

1998 - 2003

Mycophenolate mofetil for the prophylaxis of acute GvHD (multicenter German protocol), Investigator

1999 - 2001

Mycophenolate mofetil for the treatment of acute GvHD-EBMT Protocol, Iinvestigator

1993 – 1997

AREB Protokoll - Hospital Saint Louis, Paris, Investigator

1992 - 1997

An open protocol for the use of Agrelin (Anagrelide) for patients with thrombocythemia″ Project No 292, Principal Investigator; Prot. No 292024A, Principal Investigator Roberts Pharmaceutical Corporation (FDA approved protocol). Principal Investigator